Results 121 to 130 of about 136,777 (328)

OSTEOPOROSIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

open access: yesФундаментальная и клиническая медицина, 2019
Currently, rheumatologists consider osteoporosis as a complication of ankylosing spondylitis, however, in recent years, it is discussed as a comorbidity but not a complication.
TATIANA A. Raskina   +3 more
doaj  

Ankylosing spondylitis risk factors: a systematic literature review

open access: yesClinical Rheumatology, 2021
M. Hwang, Lauren K Ridley, J. Reveille
semanticscholar   +1 more source

Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment

open access: yesArthritis & Rheumatology, 2018
To investigate the impact of tumor necrosis factor inhibitor (TNFi) treatment and inflammation control on radiographic progression in early ankylosing spondylitis (AS) over 4 years.
Jun Won Park   +8 more
semanticscholar   +1 more source

Role of HLA-B27 in the pathogenesis of ankylosing spondylitis

open access: yesMolecular Medicine Reports, 2017
The study of ankylosing spondylitis (AS) has made significant progress over the last decade. Genome-wide association studies have identified and further substantiated the role of susceptibility genes outside the major histocompatibility complex locus ...
Bin Chen   +6 more
semanticscholar   +1 more source

Effects of psoriatic arthritis‐targeted drugs on bone remodeling: Clinical evidence and molecular pathways

open access: yesRheumatology &Autoimmunity, EarlyView.
Mechanisms and therapeutic targets in psoriatic arthritis: balancing inflammatory bone resorption and bone formation. Abstract Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by diverse clinical manifestations. Of particular concern, osteopenia and osteoporosis are prevalent in 45.27% and 12.94% of PsA patients, respectively ...
Yingchao Sun   +3 more
wiley   +1 more source

ERAP1 and ankylosing spondylitis

open access: yesCurrent Opinion in Immunology, 2013
The strong genetic association of ERAP1 (endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-B27 positive cases, has profound pathogenetic implications. ERAP1 is involved in trimming peptides to optimal length for binding to HLA class 1 molecules, thereby not only affecting the stability and processing ...
Keidel, S   +3 more
openaire   +4 more sources

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang   +11 more
wiley   +1 more source

Surgical anesthesia with a combination of T12 paravertebral block and lumbar plexus, sacral plexus block for hip replacement in ankylosing spondylitis: CARE-compliant 4 case reports

open access: yesBMC Anesthesiology, 2017
Background Anesthesia management for patients with severe ankylosing spondylitis scheduled for total hip arthroplasty is challenging due to a potential difficult airway and difficult neuraxial block.
Xijian Ke   +4 more
doaj   +1 more source

HLA-B27 Positivity: associated health implications [PDF]

open access: yes, 2011
HLA-B27 positivity makes the onset of autoimmune diseases such as uveitis, ankylosing spondylitis and Crohn's disease more likely to occur. Ankylosing spondylitis and Crohn's disease are two types of HLA-B27 positive diseases that demonstrate a direct ...
Cox, C. L.   +4 more
core   +1 more source

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

open access: yesAnnals of the Rheumatic Diseases, 2016
Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS).
J. Braun   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy